CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.
Commentary|Articles|September 15, 2026
A first for advanced RP: Bakall on the MOGENRY BLA acceptance and what an in-office option would mean
Author(s)Kassi Filkins, Benjamin Bakall, MD, PhD
Benjamin Bakall, MD, PhD, weighs the RESTORE efficacy and safety data, the practical realities of in-office delivery, and how genotype-independent treatment reshapes candidacy and patient counseling.
Advertisement
Advertisement
The US Food and Drug Administration (FDA) recently accepted Nanoscope Therapeutics’ biologics license application (BLA) for sonpiretigene isteparvovec (MOGENRY, formerly MCO-010), an investigational gene-agnostic optogenetic therapy for retinitis pigmentosa (RP) with severe vision loss.
Related to this article
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.
Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.
Spectacle lenses with highly aspherical lenslets are safe and effective for reducing myopia progression in US children.
Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.
Second phase 3 trial of Duravyu misses wet AMD noninferiority end point; EyePoint cuts 53% of staff to focus on DME.
The nonprescription 0.125% apraclonidine drop is approved for adults and children 12 years and older, and Alcon says each dose whitens the eye for up to 12 hours.
Advertisement
Advertisement